SC6: Methodologies for Optimizing Drug Clearance and Drug-Drug Interactions
MONDAY, APRIL 8, 2:00 – 5:00 PM
This short course will focus on concepts that will help understand how drug clearance and drug-drug interactions (DDI) can impact decisions in drug discovery and development. Topics will include drug metabolism, CYP regulation, the role of bioactivation
and how they all affect lead optimization. Common assays and methodologies for predicting clearance and drug-drug interactions will be discussed. Those scientists involved in medicinal chemistry, pharmacology and drug metabolism will benefit from
Zhengyin Yan, PhD, Principal Scientist, Department of Drug Metabolism and Pharmacokinetics, Genentech Inc.
Zhengyin Yan is currently leading the in vitro DMPK group to support small molecule drug discovery at Genentech. Previously,
he had been responsible for in vitro ADME support for nearly 17 years at Johnson & Johnson Pharmaceutical Research & Discovery in Spring House, PA. His main scientific interest includes in vitro assay development, drug metabolism, and
ADME-guided lead optimization in drug discovery.
Donglu Zhang, PhD, Principal Scientist, Department of Drug Metabolism and Pharmacokinetics, Genentech Inc.
Donglu Zhang received a PhD in Organic Chemistry from University of Utah. His current studies focus on soft-spot metabolite identification to support drug designs and to discovery ADCs. He previously worked for Bristol-Myers Squibb and ARIAD Pharmaceuticals.
He edited two books ‘Drug metabolism in drug design and development’, and ‘ADME-enabling technologies in drug design and development’. The mass defect filter (MDF) methodologies he co-invented have been widely used in high
resolution mass spectrometry for metabolite identification.